Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACTROBAN vs ACANYA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.
Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.
Impetigo due to Staphylococcus aureus and Streptococcus pyogenes,Mupirocin-sensitive infections
FDA-approved for the topical treatment of acne vulgaris in patients 12 years and older
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Apply a pea-sized amount to the entire face once daily in the evening, topical.
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Clindamycin: after topical application, terminal half-life is approximately 2-3 hours in serum, but clinical relevance is minimal due to low systemic levels. Benzoyl peroxide metabolites have a half-life of ~1-2 hours. The clinical effect is primarily local with sustained antimicrobial and keratolytic activity.
Minimal systemic absorption; rapidly metabolized to monic acid (inactive) in skin and systemically.
Clindamycin is metabolized primarily by the liver via CYP3A4. Benzoyl peroxide is metabolized to benzoic acid and then excreted in urine.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Acanya (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination applied topically. Systemic absorption is minimal. Clindamycin: <0.1% of applied dose excreted renally as parent and metabolites. Benzoyl peroxide: metabolized to benzoic acid, which is conjugated and excreted renally; <5% of applied dose appears in urine. Fecal excretion is negligible.
95% bound, primarily to albumin
Clindamycin: ~60-94% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). Benzoyl peroxide: not significantly bound; its metabolite benzoic acid is ~35% bound to albumin.
0.15-0.3 L/kg, indicating distribution primarily into extracellular fluid
After topical application, systemic concentrations are negligible; Vd not applicable for parent compound. For clindamycin after intravenous administration, Vd is ~0.6-1.2 L/kg. For benzoyl peroxide, dermal penetration is limited to stratum corneum and pilosebaceous units.
Topical: Negligible systemic absorption (<0.05% after topical application to intact skin; slightly higher (up to 1%) on abraded skin; intranasal: <0.1%
Topical bioavailability: <5% for clindamycin (due to extensive metabolism in skin and low systemic absorption); benzoyl peroxide is essentially not absorbed systemically (<2%).
No dosage adjustment necessary for topical application. For intranasal use, no adjustment required. Systemic absorption is minimal.
No dose adjustment required for renal impairment; safety in severe renal impairment not established.
No dosage adjustment necessary for topical or intranasal use. Systemic absorption is minimal.
No dose adjustment required for hepatic impairment; use caution in severe hepatic impairment.
Children 3 months and older: Same as adult dosing. Topical: apply 2% ointment/cream three times daily for 5 to 14 days. Intranasal: apply 0.5 g of 2% ointment to each nostril twice daily for 5 days.
Approved for patients aged 12 years and older. For children 12-17 years: apply a pea-sized amount to the entire face once daily.
No specific adjustments required. Use same dosing as adults. Caution in patients with renal impairment due to potential accumulation of polyethylene glycol vehicle with extensive use on open wounds or burns.
No specific dose adjustment; use smallest effective amount due to increased risk of skin atrophy in elderly.
None.
There is no FDA black box warning for Acanya.
Severe allergic reactions including anaphylaxis and angioedema; potential for superinfection with prolonged use; not for intranasal use except specific formulations.
Colitis: Clindamycin may cause pseudomembranous colitis; discontinue if diarrhea occurs.,Skin irritation: Benzoyl peroxide may cause allergic contact dermatitis and photosensitivity; avoid excessive sun exposure.,For external use only; avoid contact with eyes and mucous membranes.
Known hypersensitivity to mupirocin or any component of the formulation.
Hypersensitivity to clindamycin, benzoyl peroxide, or any component of the formulation.,History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
No known food interactions. The drug is applied topically; oral intake does not affect its action.
No specific food interactions reported. Avoid concurrent use with other topical acne products unless directed.
No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.
ACANYA (clindamycin phosphate 1.2% and benzoyl peroxide 5%) is for topical use. Systemic absorption is minimal; however, clindamycin is FDA Pregnancy Category C. Animal studies show no teratogenicity, but no adequate human studies exist. Benzoyl peroxide is Category C with unknown risk. First trimester: theoretical risk from systemic clindamycin if absorbed; second and third trimesters: minimal risk due to low absorption. No reported human teratogenicity for topical use.
Unknown if excreted in human milk; caution advised. M/P ratio not established.
Clindamycin is excreted in human milk after systemic administration; topical application yields negligible systemic levels. M/P ratio not established for topical route. Benzoyl peroxide is not known to be excreted in milk. Risk to infant is low if applied to small areas. Use caution if applied to large areas or broken skin.
No dose adjustments recommended; systemic absorption is minimal.
No dosing adjustment required for topical ACANYA in pregnancy. Systemic absorption is low and pharmacokinetic changes in pregnancy are unlikely to alter efficacy or safety. Use standard dosing: apply once daily to affected areas.
BACTROBAN (mupirocin) is a topical antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes. It is contraindicated for use on burns or large open wounds due to risk of polyethylene glycol absorption. For impetigo, apply to affected area three times daily for 5-10 days. Not effective against fungal, viral, or anaerobic infections. Monitor for local irritation; discontinue if severe. Use intranasal formulation (BACTROBAN Nasal) for MRSA decolonization.
ACANYA (clindamycin 1.2% / benzoyl peroxide 2.5%) is a fixed-dose combination gel for acne vulgaris. Apply once daily; avoid excessive application. May bleach hair or colored fabrics. Counsel patients about skin dryness, peeling, and photosensitivity. Consider alternative if significant irritation occurs.
Apply a small amount of ointment to the affected area 3 times daily, or as directed.,Wash hands before and after application to prevent spreading infection.,Do not use on large areas of broken skin or deep wounds without medical advice.,Avoid contact with eyes and mucous membranes.,Complete the full course of treatment even if symptoms improve.,Stop use and contact doctor if rash or irritation occurs.,Do not share this medication with others.
Wash affected area gently before applying a thin layer once daily.,Avoid contact with eyes, mouth, lips, and mucous membranes.,May cause skin dryness, peeling, or redness; use moisturizer if needed.,Benzoyl peroxide can bleach hair or colored fabrics; avoid contact.,Use sunscreen daily as this product increases sun sensitivity.,If severe irritation or allergic reaction occurs, stop use and consult doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACTROBAN vs ACANYA, answered by our medical review team.
BACTROBAN is a Topical Antibiotic that works by Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.. ACANYA is a Topical Antibiotic that works by Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACTROBAN and ACANYA depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACTROBAN is: Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.. The standard adult dose of ACANYA is: Apply a pea-sized amount to the entire face once daily in the evening, topical.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACTROBAN and ACANYA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACTROBAN is classified as Category C. No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.. ACANYA is classified as Category C. ACANYA (clindamycin phosphate 1.2% and benzoyl peroxide 5%) is for topical use. Systemic absorption is minimal; however, clindamycin is FDA Pregnancy Category C. Animal studies sho. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.